Familial aggregation of parkinsonism in progressive supranuclear palsy

Neurology

Volumn 73, Issue 2, 2009, Pages 98-105

  Kaat, L Donker ^a   Boon, A J W ^a   Azmani, A ^a   Kamphorst, W ^b   Breteler, M M B ^a   Anar, B ^b   Heutink, P ^b   Van Swieten, J C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

TAU PROTEIN; GRN PROTEIN, HUMAN; LRRK2 PROTEIN, HUMAN; MAPT PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEMENTIA; DISEASE TRANSMISSION; FAMILY HISTORY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; PHENOTYPE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; TREMOR; BRAIN; CASE CONTROL STUDY; DNA SEQUENCE; FAMILY; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PATHOLOGY; PEDIGREE; RISK; TAUOPATHY;

AGED; BRAIN; CASE-CONTROL STUDIES; DEMENTIA; FAMILY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; ODDS RATIO; PARKINSONIAN DISORDERS; PEDIGREE; PHENOTYPE; PROTEIN-SERINE-THREONINE KINASES; SEQUENCE ANALYSIS, DNA; SUPRANUCLEAR PALSY, PROGRESSIVE; TAU PROTEINS; TAUOPATHIES; TREMOR;

EID: 68149108192     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181a92bcc     Document Type: Article

References (38)

1. Davis PH, Golbe LI, Duvoisin RC, Schoenberg BS. Risk factors for progressive supranuclear palsy. Neurology 1988;38:1546-1552.
2. Golbe LI, Rubin RS, Cody RP, et al. Follow-up study of risk factors in progressive supranuclear palsy. Neurology 1996;47:148-154.
3. Rojo A, Pernaute RS, Fontan A, et al. Clinical genetics of familial progressive supranuclear palsy. Brain 1999;122:1233-1245.
4. Tetrud JW, Golbe LI, Forno LS, Farmer PM. Autopsyproven progressive supranuclear palsy in two siblings. Neurology 1996;46:931-934.
5. Tuite PJ, Clark HB, Bergeron C, et al. Clinical and pathologic evidence of corticobasal degeneration and progressive supranuclear palsy in familial tauopathy. Arch Neurol 2005;62:1453-1457.
6. Ros R, Gomez Garre P, Hirano M, et al. Genetic linkage of autosomal dominant progressive supranuclear palsy to 1q31.1. Ann Neurol 2005;57:634-641.
7. Stanford PM, Halliday GM, Brooks WS, et al. Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: expansion of the disease phenotype caused by tau gene mutations. Brain 2000;123:880-893.
8. Poorkaj P, Muma NA, Zhukareva V, et al. An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype. Ann Neurol 2002;52:511-516.
9. Pastor P, Ezquerra M, Tolosa E, et al. Further extension of the H1 haplotype associated with progressive supranuclear palsy. Mov Disord 2002;17:550-556.
10. van Swieten J, Spillantini MG. Hereditary frontotemporal dementia caused by Tau gene mutations. Brain Pathol 2007;17:63-73.
11. van Swieten JC, Heutink P. Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia. Lancet Neurol 2008;7:965-974.
12. Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008;7:583-590.
13. Rademakers R, Melquist S, Cruts M, et al. High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Hum Mol Genet 2005;14:3281-3292.
14. Donker Kaat L, Boon AJ, Kamphorst W, et al. Frontal presentation in progressive supranuclear palsy. Neurology 2007;69:723-729.
15. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDSSPSP international workshop. Neurology 1996;47:1-9.
16. Marder K, Levy G, Louis ED, et al. Accuracy of family history data on Parkinson's disease. Neurology 2003;61:18-23.
17. Hofman A, Breteler MM, van Duijn CM, et al. The Rotterdam Study: objectives and design update. Eur J Epidemiol 2007;22:819-829.
18. Bronner IF, Rizzu P, Seelaar H, et al. Progranulin mutations in Dutch familial frontotemporal lobar degeneration. Eur J Hum Genet 2007;15:369-374.
19. Mata IF, Kachergus JM, Taylor JP, et al. Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics 2005;6:171-177.
20. Rizzu P, Van Swieten JC, Joosse M, et al. High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. Am J Hum Genet 1999;64:414-421.
21. de Silva R, Lashley T, Gibb G, et al. Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathol Appl Neurobiol 2003;29:288-302.
22. Litvan I, Hauw JJ, Bartko JJ, et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 1996;55:97-105.
23. Williams DR, Holton JL, Strand C, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain 2007;130:1566-1576.
24. van Swieten JC, Stevens M, Rosso SM, et al. Phenotypic variation in hereditary frontotemporal dementia with tau mutations. Ann Neurol 1999;46:617-626.
25. Goldman JS, Farmer JM, Wood EM, et al. Comparison of family histories in FTLD subtypes and related tauopathies. Neurology 2005;65:1817-1819.
26. Huang W, Qiu C, von Strauss E, et al. APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-year follow-up study. Arch Neurol 2004;61:1930-1934.
27. Kurz MW, Larsen JP, Kvaloy JT, Aarsland D. Associations between family history of Parkinson's disease and dementia and risk of dementia in Parkinson's disease: a community-based, longitudinal study. Mov Disord 2006;21:2170-2174.
28. Brown J, Lantos P, Stratton M, et al. Familial progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1993;56:473-476.
29. Hofman A, Schulte W, Tanja TA, et al. History of dementia and Parkinson's disease in 1st-degree relatives of patients with Alzheimer's disease. Neurology 1989;39:1589-1592.
30. Marder K, Tang MX, Alfaro B, et al. Risk of Alzheimer's disease in relatives of Parkinson's disease patients with and without dementia. Neurology 1999;52:719-724.
31. Levy G, Louis ED, Mejia-Santana H, et al. Lack of familial aggregation of Parkinson disease and Alzheimer disease. Arch Neurol 2004;61:1033-1039.
32. Litvan I, Mangone CA, McKee A, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry 1996;60:615-620.
33. Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 2005;128:1247-1258.
34. Kobayashi T, Mori H, Okuma Y, et al. Contrasting genotypes of the tau gene in two phenotypically distinct patients with P301L mutation of frontotemporal dementia and parkinsonism linked to chromosome 17. J Neurol 2002;249:669-675.
35. Bird TD, Nochlin D, Poorkaj P, et al. A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L). Brain 1999;122(Pt 4):741-756.
36. Baba Y, Tsuboi Y, Baker MC, et al. The effect of tau genotype on clinical features in FTDP-17. Parkinsonism Relat Disord 2005;11:205-208.
37. Josephs KA, Mandrekar JN, Dickson DW. The relationship between histopathological features of progressive supranuclear palsy and disease duration. Parkinsonism Relat Disord 2006;12:109-112.
38. Uchikado H, DelleDonne A, Ahmed Z, Dickson DW. Lewy bodies in progressive supranuclear palsy represent an independent disease process. J Neuropathol Exp Neurol 2006;65:387-395.